KTN's online platform helps you to make the connections you need


The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.


The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

Innovative Medicines Initiative Updates

Call for proposals on Ebola under preparation

An ambitious IMI programme to accelerate the development of vaccines and treatments against Ebola and other filoviral haemorrhagic fevers is currently under preparation. A fast-track call for proposals is likely to be launched in the near future. More information will be published shortly on the IMI website.

According to the World Health Organization’s latest reports, over 10 000 people have contracted Ebola virus disease (EVD) in the current outbreak, and around 5 000 have died. The vast majority of cases are in just three west African countries: Guinea, Liberia and Sierra Leone. There are currently no approved treatments or vaccines for Ebola, although a number of treatments and vaccines are now being tested.

All information regarding future Calls for proposals is indicative and subject to the approval of the IMI Governing Board.

•  Read more about the EU’s Ebola research activities 


IMI 2 – Call 2 indicative topic text released

The indicative Call text for IMI’s December Call for proposals is now available on the IMI future topics page. There are seven topics are under consideration for inclusion in the Call:

Research and Innovation Actions (RIA)

•  Remote assessment for disease and relapse (RADAR), topic 1: central nervous system (CNS)

•  Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification

•  Linking clinical neuropsychiatry and quantitative neurobiology

•  The consistency approach to quality control in vaccine manufacture

•  Pertussis vaccination research

•  Knowledge Repository to enable patient focused medicine development

Coordination and Support Action (CSA)

•  Enabling platform on medicines adaptive pathway to patients

Introductory presentations on some of the topics were made during the IMI 2 Open Info Day on 30 September. The presentations are available on the IMI Open Info Day event page. Individual sessions can also be viewed on IMI’s YouTube channel. More information on the Call will be provided over the coming weeks.  

All information regarding future Calls for proposals is indicative and subject to the approval of the IMI Governing Board.


IMI Partner Search tool is ready for IMI 2 December Call

The IMI Partner Search Tool has been updated with the topics and keywords for the forthcoming December Call. Our networking tool allows you to search for potential partners - you can register and create a profile through the Partner Search Tool portal on the IMI home page. Participants in IMI consortia also recommend using your existing contacts and networks to identify possible collaborators who may be interested in working on a proposal. Other methods of publicising your expertise include registering on the European Commission's partner search portal CORDIS and posting your search criteria through relevant social networking sites  – for example IMI’s LinkedIn group and the Horizon 2020 LinkedIn group In addition you can contact your State Representatives Group (SRG) member who has been involved in all aspects of the IMI Call process. 

Finally there are other partner search platforms relevant to life science research – Fit for Health offers the EU Partner Match portal and the German National Contact Point and SRG member offers a dedicated partner search platformfor IMI ‘s Calls. Due to potential conflicts of interest, the IMI Programme Officeis not able to recommend or help with personally matchmaking potential participants in its Calls.


Reminder: IMI 2 – Call 1 deadline approaching

The deadline for submitting proposals in response to IMI 2 – Call 1 is 12 November at 17:00 Central European Time (CET / Brussels time). If you’re applying for funding under this first Call, or considering applying for future Calls, don’t forget the following top tips for applicants.

•  Read and understand the Call documents! Yes, it takes some time, but it is worth the effort.

•  If something isn't clear, or if you have questions, contact us - we're here to help you.

•  Don't forget to finalise your application in our submission tool. No finalisation = no evaluation!


IMI 2 Open Info Day – presentations and videos now available

IMI held its IMI 2 Open Info Day in Brussels on Tuesday 30 September 2014. The event was well-attended, with more than 285 people participating either in person or remotely via the webcast.  Full details of the presentation given during each of the sessions are now available on the event web page. Videos of the day are also available on IMI's YouTube channel.


IMI holds joint event with C-Path on the role of PPPs

IMI and C-Path will hold a joint event under the heading ‘accelerating the development of drugs, diagnostics, and devices through partnerships that expand the precompetitive space’. The event, which is the second annual meeting of the two organisations, takes place on 3 rd December in Bethesda, Maryland, USA.

Collaborations between industry, regulatory agencies, academia and patient groups are increasing. This event aims to identify and address the challenges and opportunities of Public Private Partnerships (PPPs), e.g. mechanisms for assessing productivity and enhancing effectiveness, how to coordinate efforts and avoid duplication, and how to adopt best practices on data sharing.   

A cross-sectorial panel of speakers will give their perspectives on the role PPPs can play in delivering innovative tools and methodologies for a more streamlined medical product development. Discussions during the day will focus on how PPPs advance regulatory science and leverage global efforts, experiences with collaboration in the area of safety biomarkers, and the value of data sharing.    

The agenda and information on how to register are available on the event website.      


IMI featured in report to Obama on antibiotic resistance

IMI and its antimicrobial resistance programme ND4BB (‘New Drugs for Bad Bugs’) were mentioned in a report to US president Barack Obama on combating antibiotic resistance.

The report mentions that through IMI and its ND4BB programme, the EU has expanded its research efforts with respect to antibiotic resistance. The publication outlines that the EU is funding work on Gram‐negative bacteria under the ND4BB programme, highlighting that ‘much more is needed and there are good opportunities for transatlantic collaboration on this topic’.

The report was published in September 2014 by the President’s Council of Advisors on Science and Technology. It offers practical recommendations to the US federal government for strengthening its ability to combat the rise in antibiotic-resistant bacteria.

•  Read the report to President Obama ‘Combating antibiotic resistance’ 

•  Learn more about IMI’s ND4BB antimicrobial resistance programme